Stereotactic Surgery Devices Market | Unlocking Potential in Minimally Invasive Brain Interventions

The Stereotactic Surgery Devices Market is expected to increase from US$ 26.34 billion in 2023 to US$ 39.36 billion by 2033.

Overall Stereotactic Surgery Devices Market

The primary factors driving demand for Stereotactic Surgery Devices are rising demand for minimally invasive operations, increasing cancer prevalence, and technological improvement in stereotactic surgery equipment.

With governments and various healthcare professionals focused on research and development and investments in the healthcare sector, the next developments might drive the expansion of the stereotactic surgery instruments industry. Furthermore, the increasing use of these devices in patients with arteriovenous malformations, epilepsy, and Parkinson's disease is likely to provide a substantial boost to the market in the future years. The rising prevalence of these medical disorders is also projected to accelerate the adoption of stereotactic surgery instruments.

One of the most effective cancer treatments is radiosurgery. Stereotactic radiosurgery allows for the precise treatment of malignancies with high-dose radiation. Technical improvements in stereotactic radiosurgery aid in boosting treatment precision. Moreover, stereotactic radiosurgery aids in concentrating radiation dose on tumor cell lining, reducing the influence of radiation on adjacent healthy tissues.

Stereotactic radiosurgery and accompanying equipment are incorporating a variety of technologies. Radiosurgery therapies based on Varian technology help physicians treat many forms of cancer. Varian Medical Systems provide the Edge radiosurgery system, which is based on Varian technology and includes other technological components. Clinics, for example, can employ this modern equipment to perform streamlined stereotactic radiosurgery with speed and precision.

Despite the numerous benefits of stereotactic surgery, the expensive cost of stereotactic instruments is projected to stymie market expansion. Stereotactic radiosurgery can be delivered using ordinary Linear Accelerators (LINACs) or systems such as Gamma Knife. Unfortunately, many nations lack the financing and money to maintain such expensive radiation systems, which may have a negative impact on market growth.

Key Points from the Stereotactic Surgery Devices Market

  • The market is expected to surpass US$ 39.36 billion by 2033.
  • Rising surgical procedures, growing cancer prevalence, and increased government awareness campaigns are key factors boosting market expansion.
  • Stereotactic Surgery Devices market is expected to hold a CAGR of 4.1% during the forecast period 2023 to 2033.
  • North America dominated the Stereotactic Surgery Devices market.

Download Sample Report for Key Insights into the Market: https://www.futuremarketinsights.com/reports/sample/rep-gb-16922

Major players in the market are:

  • Koninklijke Philips N.V.
  • Hitachi Medical Systems
  • Huiheng Group
  • Siemens Ag
  • Elekta AB
  • Varian Medical Systems
  • IBA
  • Accuray Incorporated

Comments

Post a Comment

Popular posts from this blog

Handheld Ultrasound Scanners Market Will Generate Booming Growth Opportunities to 2032

Image
According to industry predictions, the global Handheld Ultrasound Scanners Market Demand will increase at a CAGR of 9.1% from 2022 to 2032, reaching a value of US$ 472.1 million by the end of 2022. By 2032, sales are estimated to exceed a valuation of roughly US$ 1.1 billion. With an expected 83.6% market share in 2021, the wired modality now leads the sector. Because they connect to Bluetooth or Wi-Fi devices such as mobile phones or tablets, Handheld Ultrasound Scanners are gaining appeal among both medical professionals and non-radiologists. These devices improve networking systems and ease picture transfer to medical facilities. Global Handheld Ultrasound Scanners Market: Dynamics         Technological advancements in medical imaging devices, increased use of Handheld Ultrasound Scanners among non-radiologists, benefits from international trade agreements, increased importing of imaging diagnostics systems, increased use of Handheld Ultrasound Scanners in emergency medical service
Read more

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

Antidiabetics Market to reach US$ 223 billion by 2032, growing at a 9.6% CAGR from 2022 to 2032 | Future Market Insights, Inc.

Image
The global Antidiabetics Market is expected to earn US$ 223 billion while expanding at a CAGR of 9.6% during the forecast period. The rising prevalence of diabetes worldwide can be attributed to the market's expansion. The ageing baby boomer population is another factor driving the market during the forecast period. According to the International Diabetes Federation, the global diabetes incidence will increase from 366 million in 2011 to 552 million by 2030. During the forecast period, the industry is expected to benefit from a significant increase in the number of diabetic patients. Furthermore, new product development is expected to benefit the market in the near future. For example, Novo Nordisk, a Danish pharmaceutical company, announced the launch of oral semaglutide for the treatment of Type 2 diabetes in India in January 2022. Furthermore, the development of advanced pumps based on smart technologies like AI and ML is expected to open up a slew of new doors. For exampl
Read more